Investors seeking momentum may have Vanguard Healthcare ETF (VHT - Free Report) on radar now. The fund recently hit a new 52-week high. Shares of VHT are up approximately 29.2% from the 52-week low of $120.38/share.
But could there be more gains ahead for this ETF? Let’s take a look at the fund and the near-term outlook to get a better idea of where it might be headed.
VHT in Focus
VHT focuses on providing exposure to healthcare stocks in the U.S. equity markets. It charges 10 basis points in fee per year and has top holdings in Johnson & Johnson (JNJ - Free Report) , Pfizer (PFE - Free Report) and Unitedhealth (UNH - Free Report) with 9.6%, 5.9% and 5.2% allocation, respectively (as of Sep 30, 2017) (see all Health Care ETFs here).
Why the Move?
The earnings season is off to a strong start with companies in the sector beating estimates. In a latest executive order, Trump aimed at scrapping a key component of Obamacare. The President said that he wanted to end subsidies to insurers that cost $7 billion this year and help millions of low-income Americans pay medical expenses. However, the uncertainty was reduced to some extent as news of the two political parties coming to a bipartisan deal started doing the rounds. Senators of both parties said they reached a deal to stabilize Obamacare for the short term and allow insurer subsidies. This in turn led to a rally in healthcare stocks.
More Gains Ahead?
Currently, VHT has a Zacks ETF Rank #2 (Buy) with a Medium Risk outlook. Moreover, the ETF has a weighted alpha of 22.6. So, there is a promising outlook ahead for those who want to ride this surging ETF a shade further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>